Published in J Urol on April 01, 2007
Relationship Between Lymph Node Dissection and Prognosis in High-risk NMIBC | NCT05123625
Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol (2012) 1.13
Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. Can Urol Assoc J (2011) 1.07
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol (2012) 0.97
The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J (2009) 0.91
Optimized management in patients with bladder cancer. Cent European J Urol (2015) 0.88
The arguments for an early cystectomy in patients with urothelial carcinoma. Cent European J Urol (2014) 0.88
Survival up to 5-15 years in young women following genital sparing radical cystectomy and neobladder: oncological outcome and quality of life. Single-surgeon and single-institution experience. Cent European J Urol (2015) 0.88
Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. World J Urol (2010) 0.87
Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol (2009) 0.87
Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy. World J Urol (2011) 0.81
Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer. PLoS One (2015) 0.80
Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. Br J Cancer (2014) 0.80
Proactive approach to treat high-grade lamina-invasive bladder cancer. Indian J Urol (2011) 0.78
Treatment and survival in patients with recurrent high-risk non-muscle-invasive bladder cancer. Urol Oncol (2014) 0.77
Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J (2014) 0.77
Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease. Bladder Cancer (2015) 0.76
Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer. Oncotarget (2016) 0.76
Treatment options in non-muscle-invasive bladder cancer after BCG failure. Indian J Urol (2015) 0.76
Genomic characterization of high-risk non-muscle invasive bladder cancer. Oncotarget (2016) 0.75
Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know? Bladder Cancer (2015) 0.75
Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer (2016) 0.75
The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer. Adv Urol (2015) 0.75
Risk factor assessment in high-risk, bacillus Calmette-Guérin-treated, non-muscle-invasive bladder cancer. Res Rep Urol (2017) 0.75
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol (2008) 5.64
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol (2007) 5.03
Epidemiology and risk factors of urothelial bladder cancer. Eur Urol (2012) 4.45
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15
Empirical study of data sharing by authors publishing in PLoS journals. PLoS One (2009) 4.09
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol (2006) 3.46
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ (2010) 3.38
Low annual caseloads of United States surgeons conducting radical prostatectomy. J Urol (2009) 3.04
The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol (2010) 3.02
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol (2008) 2.88
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med (2015) 2.71
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol (2008) 2.57
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. Trials (2010) 2.54
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (2008) 2.53
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol (2006) 2.50
Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer (2014) 2.48
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters. Eur Urol (2011) 2.36
Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches. J Urol (2010) 2.32
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol (2007) 2.30
Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol (2010) 2.27
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer (2009) 2.18
A simple schema for informed decision making about prostate cancer screening. Ann Intern Med (2014) 2.12
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. BMJ (2004) 2.03
Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int (2006) 2.00
Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol (2004) 1.97
Variations among experienced surgeons in cancer control after open radical prostatectomy. J Urol (2010) 1.93
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol (2002) 1.90
Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J Clin Oncol (2006) 1.88
Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol (2007) 1.87
Decision curve analysis: a discussion. Med Decis Making (2008) 1.87
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol (2011) 1.85
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82
The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol (2011) 1.81
Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol (2009) 1.78
Prostate cancer: estimating the benefits of PSA screening. Nat Rev Urol (2009) 1.76
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol (2007) 1.76
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer (2006) 1.75
Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol (2011) 1.71
Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology (2005) 1.69
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. J Urol (2010) 1.66
Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. Eur Urol (2008) 1.66
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol (2003) 1.63
Acupuncture in the treatment of upper-limb lymphedema: results of a pilot study. Cancer (2013) 1.62
Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer (2008) 1.62
Complications after radical cystectomy: analysis of population-based data. Urology (2006) 1.60
Massage therapy for symptom control: outcome study at a major cancer center. J Pain Symptom Manage (2004) 1.60
Critical review of prostate cancer predictive tools. Future Oncol (2009) 1.57
Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol (2011) 1.55
Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer (2006) 1.53
Urachal carcinoma: contemporary surgical outcomes. J Urol (2007) 1.53
Carcinoma in a bladder diverticulum: presentation and treatment outcome. J Urol (2003) 1.52